- Home
- Products
- Customized ADCs
- CD4
- Anti-CD4 (Priliximab)-MC-Vc-PAB-SN38 ADC
Anti-CD4 (Priliximab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-864)
This ADC product is comprised of an anti-CD4 monoclonal antibody conjugated via a MC-Vc-PAB linker to SN38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, SN-38 binds to DNA, causes DNA damage.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CD4
- Alternative Names
- CD4; CD4 molecule; CD4 antigen (p55) , T cell surface glycoprotein CD4; T-cell surface glycoprotein CD4; CD4 receptor; CD4 antigen (p55); T-cell surface antigen T4/Leu-3; CD4mut;
- Target Entrez Gene ID
- 920
- Target UniProt ID
- P01730
- Overview
- This gene encodes a membrane glycoprotein of T lymphocytes that interacts with major histocompatibility complex class II antigenes and is also a receptor for the human immunodeficiency virus. This gene is expressed not only in T lymphocytes, but also in B cells, macrophages, and granulocytes. It is also expressed in specific regions of the brain. The protein functions to initiate or augment the early phase of T-cell activation, and may function as an important mediator of indirect neuronal damage in infectious and immune-mediated diseases of the central nervous system. Multiple alternatively spliced transcript variants encoding different isoforms have been identified in this gene.
- Overview
- Chimeric Anti-CD4 IgG1-kappa antibody, Priliximab
- Generic name
- Priliximab
- Host animal
- Mouse
- Species Reactivity
- Human
- Name
- MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- SN-38 (7-ethyl-10-hydroxycamptothecin)
- Description
- SN38 (7-ethyl-10-hydroxy camptothecin) is an active metabolite of the cancer prodrug, irinotecan, with the ability of inhibiting Topoisomerase I, which is belong to the camptothecin family. SN-38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-PCSK9 (Lodelcizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1691)
- Anti-ITGA4+ITGB7 (Crenezumab)-SPDB-DM4 ADC (CAT#: ADC-W-2499)
- Anti-MSLN (clone h7D9.v3)-Mc-VC-PABC-MMAF ADC (CAT#: ADC-W-456)
- Anti-C. albicans Hsp90 (Efungumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2197)
- Anti-DLL4 (Demcizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1021)
- Anti-ERBB2 (trastuzumab)-Aminocaproyl-MMAD ADC (CAT#: ADC-W-632)
- Anti-GD2 (Dinutuximab)-SPDB-DM4 ADC (CAT#: ADC-W-2007)
- Anti-MS4A1 (Afutuzumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1572)
- Anti-IL13 (Tralokinumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1297)
- Anti-CD22 (Pinatuzumab)-SPDB-DM4 ADC (CAT#: ADC-W-2533)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-864. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-892 | Anti-CD4 (Ibalizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-889 | Anti-CD4 (Cedelizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-891 | Anti-CD4 (Ibalizumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-893 | Anti-CD4 (Ibalizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-887 | Anti-CD4 (Cedelizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
CAT# | Product Name | Linker | Payload |
ADC-W-2596 | Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2581 | Anti-CEACAM5-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2618 | Anti-MS4A1-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2623 | Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2592 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
CAT# | Product Name | Linker | Payload |
ADC-W-2624 | Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-472 | Anti-CEACAM5-Phy-lys-SN-38 ADC | Phy-lys (Phenylalanine-lysine) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2569 | Anti-MUC16 (Sofituzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2587 | Anti-EGFR (Zalutumumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2593 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.